| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Imperial Cancer Research Fund, Clare Hall Laboratories, South Mimms, Potters Bar, Herts EN6 3LD, United Kingdom [I. C. G., N. K. S.]; Department of Surgery, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, United Kingdom [S. M. A. P., J. P. N.]; Central Manchester Healthcare National Health Service Trust, St. Mary's Hospital for Women and Children, Manchester M13 OJH, United Kingdom [S. J. L.]; and Genethon, 1 rue de l'Internationale, 91000 Evry, France [J. W.]
Loss of the chromosomal region 10q23–25 is a frequent event in the progression of prostate adenocarcinoma. A candidate tumor suppressor gene from this region, Mxi1 at 10q25, has recently been shown to be mutated in a small number of prostate tumors. To more strictly define those regions of 10q loss that are likely to be involved in tumor advancement, we have constructed a detailed deletion map spanning 10q23–25 that incorporates Mxi1. Sixty-two % (23 of 37) of tumors analyzed exhibited some degree of 10q23–25 loss. Our data suggest the presence of a prostate tumor suppressor gene(s) near the 10q23–24 boundary, which was deleted in the overwhelming majority (22 of 23) of tumors showing loss. In contrast, specific loss of Mxi1, as opposed to loss of other 10q23–25 regions or of the entire region, was observed in only 1 of 23 tumors and was accompanied by loss of markers at the 10q23–24 boundary. Furthermore, we failed to detect any mutations in Mxi1 in those tumors showing Mxi1-associated marker loss by either single-strand conformation polymorphism analysis or direct DNA sequencing.
1 Supported by the Imperial Cancer Research Fund.
2 To whom requests for reprints should be addressed.
Received 7/31/95. Accepted 9/20/95.
This article has been cited by other articles:
|
|
 |
|
  W. Zhang, J. Zhu, C. L. Efferson, C. Ware, J. Tammam, M. Angagaw, J. Laskey, K. A. Bettano, S. Kasibhatla, J. F. Reilly, et al. Inhibition of Tumor Growth Progression by Antiandrogens and mTOR Inhibitor in a Pten-Deficient Mouse Model of Prostate Cancer Cancer Res., September 15, 2009; 69(18): 7466 - 7472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Blando, M. Portis, F. Benavides, A. Alexander, G. Mills, B. Dave, C. J. Conti, J. Kim, and C. L. Walker PTEN Deficiency Is Fully Penetrant for Prostate Adenocarcinoma in C57BL/6 Mice via mTOR-Dependent Growth Am. J. Pathol., May 1, 2009; 174(5): 1869 - 1879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. SUN, J. HUANG, T. HOMMA, D. KITA, H. KLOCKER, G. SCHAFER, P. BOYLE, and H. OHGAKI Genetic Alterations in the PI3K Pathway in Prostate Cancer Anticancer Res, May 1, 2009; 29(5): 1739 - 1743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Sun, D. K. St. Clair, F. Fang, G. W. Warren, V. M. Rangnekar, P. A. Crooks, and W. H. St. Clair The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-{kappa}B inhibition and enhanced by the presence of PTEN Mol. Cancer Ther., September 1, 2007; 6(9): 2477 - 2486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Delpuech, B. Griffiths, P. East, A. Essafi, E. W.-F. Lam, B. Burgering, J. Downward, and A. Schulze Induction of Mxi1-SR{alpha} by FOXO3a Contributes to Repression of Myc-Dependent Gene Expression Mol. Cell. Biol., July 1, 2007; 27(13): 4917 - 4930. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ma, J. Teruya-Feldstein, N. Behrendt, Z. Chen, T. Noda, O. Hino, C. Cordon-Cardo, and P. P. Pandolfi Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression Genes & Dev., August 1, 2005; 19(15): 1779 - 1786. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Lieberfarb, M. Lin, M. Lechpammer, C. Li, D. M. Tanenbaum, P. G. Febbo, R. L. Wright, J. Shim, P. W. Kantoff, M. Loda, et al. Genome-wide Loss of Heterozygosity Analysis from Laser Capture Microdissected Prostate Cancer Using Single Nucleotide Polymorphic Allele (SNP) Arrays and a Novel Bioinformatics Platform dChipSNP Cancer Res., August 15, 2003; 63(16): 4781 - 4785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. J. Halvorsen, S. A. Haukaas, and L. A. Akslen Combined Loss of PTEN and p27 Expression Is Associated with Tumor Cell Proliferation by Ki-67 and Increased Risk of Recurrent Disease in Localized Prostate Cancer Clin. Cancer Res., April 1, 2003; 9(4): 1474 - 1479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Q. Zhang, S. A. Salzman, D. J. Reding, B. K. Suarez, W. J. Catalona, and J. K. Burmester Genetics of Prostate Cancer Clin. Med. Res., January 1, 2003; 1(1): 21 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Davies, S. J. Kim, N. U. Parikh, Z. Dong, C. D. Bucana, and G. E. Gallick Adenoviral-mediated Expression of MMAC/PTEN Inhibits Proliferation and Metastasis of Human Prostate Cancer Cells Clin. Cancer Res., June 1, 2002; 8(6): 1904 - 1914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Shou, R. Soriano, S. W. Hayward, G. R. Cunha, P. M. Williams, and W.-Q. Gao Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression PNAS, March 5, 2002; 99(5): 2830 - 2835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-T. Dong, C.-L. Li, T. W. Sipe, and H. F. Frierson Jr. Mutations of PTEN/MMAC1 in Primary Prostate Cancers from Chinese Patients Clin. Cancer Res., February 1, 2001; 7(2): 304 - 308. [Abstract] [Full Text]
|
|
|
|
|
|
J. C. Alers, P.-J. Krijtenburg, A. N. Vis, R. F. Hoedemaeker, M. F. Wildhagen, W. C. J. Hop, T. H. van der Kwast, F. H. Schroder, H. J. Tanke, and H. van Dekken Molecular Cytogenetic Analysis of Prostatic Adenocarcinomas from Screening Studies : Early Cancers May Contain Aggressive Genetic Features Am. J. Pathol., February 1, 2001; 158(2): 399 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Abate-Shen and M. M. Shen Molecular genetics of prostate cancer Genes & Dev., October 1, 2000; 14(19): 2410 - 2434. [Full Text]
|
|
|
|
 |
|
 M. S FORREST, S. M EDWARDS, R. A HAMOUDI, D. P DEARNALEY, A. ARDEN-JONES, A. DOWE, A. MURKIN, J. KELLY, M D. TEARE, D. F EASTON, et al. No evidence of germline PTEN mutations in familial prostate cancer J. Med. Genet., March 1, 2000; 37(3): 210 - 212. [Full Text]
|
|
|
|
|
|
X. Zhou, B. L. Kemp, F. R. Khuri, D. Liu, J. J. Lee, W. Wu, W. K. Hong, and L. Mao Prognostic Implication of Microsatellite Alteration Profiles in Early-Stage Non-small Cell Lung Cancer Clin. Cancer Res., February 1, 2000; 6(2): 559 - 565. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Tamura, J. Gu, H. Tran, and K. M. Yamada PTEN Gene and Integrin Signaling in Cancer J Natl Cancer Inst, November 3, 1999; 91(21): 1820 - 1828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. McMenamin, P. Soung, S. Perera, I. Kaplan, M. Loda, and W. R. Sellers Loss of PTEN Expression in Paraffin-embedded Primary Prostate Cancer Correlates with High Gleason Score and Advanced Stage Cancer Res., September 1, 1999; 59(17): 4291 - 4296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Knuutila, Y. Aalto, K. Autio, A.-M. Bjorkqvist, W.'e. El-Rifai, S. Hemmer, T. Huhta, E. Kettunen, S. Kiuru-Kuhlefelt, M. L. Larramendy, et al. DNA Copy Number Losses in Human Neoplasms Am. J. Pathol., September 1, 1999; 155(3): 683 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Davies, D. Koul, H. Dhesi, R. Berman, T. J. McDonnell, D. McConkey, W. K. A. Yung, and P. A. Steck Regulation of Akt/PKB Activity, Cellular Growth, and Apoptosis in Prostate Carcinoma Cells by MMAC/PTEN Cancer Res., June 1, 1999; 59(11): 2551 - 2556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Cooney, H. C. Tsou, E. M. Petty, S. Miesfeldt, X. L. Ping, A. C. Gruener, and M. Peacocke Absence of PTEN Germ-Line Mutations in Men with a Potential Inherited Predisposition to Prostate Cancer Clin. Cancer Res., June 1, 1999; 5(6): 1387 - 1391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Wu, B. L. Kemp, M. L. Proctor, A. F. Gazdar, J. D. Minna, W. K. Hong, and L. Mao Expression of DMBT1, a Candidate Tumor Suppressor Gene, Is Frequently Lost in Lung Cancer Cancer Res., April 1, 1999; 59(8): 1846 - 1851. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ramaswamy, N. Nakamura, F. Vazquez, D. B. Batt, S. Perera, T. M. Roberts, and W. R. Sellers Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway PNAS, March 2, 1999; 96(5): 2110 - 2115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ruijter, C. van de Kaa, G. Miller, D. Ruiter, F. Debruyne, and J. Schalken Molecular Genetics and Epidemiology of Prostate Carcinoma Endocr. Rev., February 1, 1999; 20(1): 22 - 45. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. Stone, M Murone, S Luoh, W Ye, M. Armanini, A Gurney, H Phillips, J Brush, A Goddard, F. de Sauvage, et al. Characterization of the human suppressor of fused, a negative regulator of the zinc-finger transcription factor Gli J. Cell Sci., January 12, 1999; 112(23): 4437 - 4448. [Abstract] [PDF]
|
|
|
|
|
|
C. V. Dang c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism Mol. Cell. Biol., January 1, 1999; 19(1): 1 - 11. [Full Text] [PDF]
|
|
|
|
|
|
W.'e. El-Rifai, M. Sarlomo-Rikala, S. Knuutila, and M. Miettinen DNA Copy Number Changes in Development and Progression in Leiomyosarcomas of Soft Tissues Am. J. Pathol., September 1, 1998; 153(3): 985 - 990. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
